Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors.
作者信息
Vistisen Simon T, Bodilsen Jacob, Scheeren Thomas W L, Simonsen Ulf
机构信息
From the Department of Clinical Medicine, Aarhus University, Aarhus (STV), Department of Infectious Diseases, Aalborg University Hospital, Aalborg, Denmark (JB), Department of Anaesthesiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands (TWLS) and Department of Biomedicine, Aarhus University, Aarhus, Denmark (US).
出版信息
Eur J Anaesthesiol. 2020 Sep;37(9):739-742. doi: 10.1097/EJA.0000000000001277.
Abstract
摘要
相似文献
1
Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors.接受肾素-血管紧张素-醛固酮抑制剂治疗的COVID-19患者的风险及预后
Eur J Anaesthesiol. 2020 Sep;37(9):739-742. doi: 10.1097/EJA.0000000000001277.
2
RAAS blockers in hypertension posing a higher risk toward the COVID-19.用于治疗高血压的肾素-血管紧张素-醛固酮系统（RAAS）阻滞剂会增加感染新型冠状病毒肺炎（COVID-19）的风险。
Dermatol Ther. 2020 Jul;33(4):e13501. doi: 10.1111/dth.13501. Epub 2020 Jun 16.
3
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
4
Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.血管紧张素转化酶抑制剂改善合并高血压的 COVID-19 患者的临床结局。
Emerg Microbes Infect. 2020 Dec;9(1):757-760. doi: 10.1080/22221751.2020.1746200.
5
[Renin-angiotensin system blockers and COVID-19 infection].[肾素-血管紧张素系统阻滞剂与新型冠状病毒肺炎感染]
Hipertens Riesgo Vasc. 2020 Jul-Sep;37(3):99-100. doi: 10.1016/j.hipert.2020.04.002. Epub 2020 Apr 16.
6
Renin-angiotensin-aldosterone system inhibitors and COVID-19.肾素-血管紧张素-醛固酮系统抑制剂与2019冠状病毒病
CMAJ. 2020 May 19;192(20):E553-E554. doi: 10.1503/cmaj.200619. Epub 2020 Apr 24.
7
Relationship between angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and SARS-CoV-2 infection: where are we?血管紧张素转换酶抑制剂、血管紧张素 II 受体阻滞剂与新型冠状病毒 2 型感染之间的关系：我们目前的进展如何？
Minerva Cardioangiol. 2020 Aug;68(4):339-346. doi: 10.23736/S0026-4725.20.05271-8. Epub 2020 May 29.
8
Renin-angiotensin system blockers and severe acute respiratory syndrome coronavirus 2.肾素-血管紧张素系统阻滞剂与严重急性呼吸综合征冠状病毒 2.
Arch Cardiovasc Dis. 2020 Aug-Sep;113(8-9):572-578. doi: 10.1016/j.acvd.2020.07.001. Epub 2020 Aug 17.
9
Renin-angiotensin system and SARS-CoV-2 interaction: underlying mechanisms and potential clinical implications.肾素-血管紧张素系统与新型冠状病毒2的相互作用：潜在机制及临床意义
Gen Physiol Biophys. 2020 May;39(3):203-204. doi: 10.4149/gpb_2020019.
10
Outcomes of renin-angiotensin-aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis.肾素-血管紧张素-醛固酮系统阻滞剂在新型冠状病毒肺炎患者中的疗效：一项系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):335-337. doi: 10.1093/ehjcvp/pvaa074.
引用本文的文献
1
Changes in olfaction and taste in patients hospitalized for COVID-19 and their relationship to patient evolution during hospitalization.COVID-19 住院患者嗅觉和味觉变化及其与住院期间患者病情演变的关系。
Braz J Otorhinolaryngol. 2022 Nov-Dec;88 Suppl 5(Suppl 5):S75-S82. doi: 10.1016/j.bjorl.2021.11.002. Epub 2021 Nov 24.
2
Effects of angiotensin II receptor blocker usage on viral load, antibody dynamics, and transcriptional characteristics among COVID-19 patients with hypertension.血管紧张素 II 受体阻滞剂的使用对高血压合并 COVID-19 患者病毒载量、抗体动力学和转录特征的影响。
J Zhejiang Univ Sci B. 2021 Apr 15;22(4):330-340. doi: 10.1631/jzus.B2000730.
Zotero 插件